A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations

MLA

Keisuke Baba, et al. “A Phase I Study of Afatinib for Patients Aged 75 or Older with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.” Medical Oncology (Northwood, London, England), vol. 35, no. 3, Jan. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....40de9b9d920d87b0b65e6dc7f1d213dd&authtype=sso&custid=ns315887.

APA

Keisuke Baba, Yukihiro Hasegawa, Yoshiko Ishioka, Hideyuki Nakagawa, Sadatomo Tasaka, Hisashi Tanaka, Kageaki Taima, Yoshihito Tanaka, Shingo Takanashi, & Masamichi Itoga. (2018). A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations. Medical Oncology (Northwood, London, England), 35(3).

Chicago

Keisuke Baba, Yukihiro Hasegawa, Yoshiko Ishioka, Hideyuki Nakagawa, Sadatomo Tasaka, Hisashi Tanaka, Kageaki Taima, Yoshihito Tanaka, Shingo Takanashi, and Masamichi Itoga. 2018. “A Phase I Study of Afatinib for Patients Aged 75 or Older with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.” Medical Oncology (Northwood, London, England) 35 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....40de9b9d920d87b0b65e6dc7f1d213dd&authtype=sso&custid=ns315887.